Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

In recent years, a combination of two demographic phenomena, an increase in the number
of older people in the population and an increase in the incidence of lung cancer with age …

Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …

Lung cancer is primarily diagnosed during the advanced stage of disease, at which stage
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

We conducted a case control study of selective cyclooxygenase-2 (COX-2) blocking agents
and lung cancer. A total of 492 newly diagnosed lung cancer cases were ascertained during …

Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau …

Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only
active supportive care because of poor performance status or presence of several …